Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001381 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00001381: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00001381 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001381, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.
Interventions
- DRUG suramin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1994-03 |
| Est. Completion | 2000-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001381
The ClinicalTrials.gov registry entry for NCT00001381 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which suramin is the first listed.
NCT00001381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001381 about?
NCT00001381 is a clinical study titled "A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder". Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.
What is the current status of trial NCT00001381?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 1994-03. Estimated completion is 2000-12.
What interventions are being tested in trial NCT00001381?
The interventions under investigation include: suramin (DRUG).
Who is sponsoring clinical trial NCT00001381?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.